Boehringer Ingelheim announced that an additional $120 million will be invested in the vaccine plant currently under construction in Lyon-Jonage in France. Previously the company announced that the initial phase would cost $240 million, representing the largest veterinary vaccine facility in the E.U. and is scheduled to produce vaccines in early 2023.
The extension will allow the facility to satisfy the demand for vaccines especially for catastrophic diseases that transcend boundaries. The executive responsible for animal health at Boehringer Ingelheim stated, “Our business is positioned to be at the forefront of innovation in protecting animals and subsequently humans from trans-boundary and emerging diseases. This additional investment in our production capabilities will help governments around the world as well as other customers ensure a rapid response to new threats”.